Jagsonpal Pharma Reports Positive Financial Results, Receives 'Hold' Call from MarketsMOJO

Jagsonpal Pharmaceuticals, a smallcap company in the pharmaceuticals and drugs industry, has recently declared its financial results for the quarter ending September 2024. The stock has been given a 'Hold' call by MarketsMOJO. According to the financials, the company has shown positive performance in the quarter, with a score of 18, which is an improvement from the previous score of 6 in the last 3 months. This indicates a positive trend for the company. One of the key factors contributing to this positive performance is the growth in Profit Before Tax less Other Income (PBT) - Quarterly, which has increased by 155.7% to Rs 13.72 crore compared to the average PBT of the previous four quarters, which was Rs 5.37 crore. This shows a very positive trend in the near term for PBT. Similarly, the Profit After Tax (PAT) - Quarterly has also shown a significant growth of 101.3% to Rs 11.46 crore compared to the average PAT of the previous four quarters, which was Rs 5.69 crore. This indicates a very positive trend in the near term for PAT. The company has also seen a growth in Net Sales - Quarterly, which has increased by 42.3% to Rs 74.69 crore compared to the average Net Sales of the previous four quarters, which was Rs 52.50 crore. This shows a very positive trend in the near term for sales. In fact, the company has achieved its highest Net Sales in the last five quarters, which is a positive sign for its sales trend. The Operating Profit (PBDIT) - Quarterly has also shown a positive trend, with the highest at Rs 16.28 crore in the last five quarters. This indicates a positive trend in the near term for operating profit. The company's efficiency has also improved, as seen in the Operating Profit Margin - Quarterly, which is at its highest at 21.80% in the last five quarters. Overall, Jagsonpal Pharma has shown a positive trend in its financial performance, with the highest PBT and PAT in the last five quarters. This has also resulted in higher earnings per share (EPS) of Rs 4.33 and a higher dividend per share (DPS) of Rs 5.00 in the last five years. The company has also maintained a high dividend payout ratio (DPR) of 58.85%, indicating its commitment to distributing profits to shareholders. In conclusion, Jagsonpal Pharmaceuticals has shown a positive financial performance in the quarter ending September 2024, with a 'Hold' call from MarketsMOJO. The company's efficiency and profitability have improved, and it has also been able to generate higher earnings and dividends for its shareholders.